A new vaccine adjuvant system combining the T-cell costimulatory molecule SA-4-1BBL with the TLR4 agonist monophosphoryl lipid was evaluated for its ability to enhance the effects of tumor-associated antigens. This evidence concerns the gene TLR4 and neoplasm.